

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/110741> since 2021-04-26T12:08:04Z

Published version:

DOI:10.1097/FTD.0b013e31824bf778

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 **TITLE: Inosine triphosphatase polymorphisms and ribavirin**
2 **pharmacokinetics as determinants of ribavirin-associate anemia in patients**
3 **receiving standard anti-HCV treatment.**

4 **Authors:** Antonio D'Avolio (BSc, MSc, SM)¹, Alessia Ciancio (MD, PhD)², Marco Siccardi
5 (BSc, MSc, PhD)¹, Antonina Smedile (MD)², Lorena Baietto (BSc, MSc)¹, Marco Simiele (BSc,
6 MSc)¹, Diego Aguilar Marucco (MD)¹, Giuseppe Cariti (MD)¹, Andrea Calcagno (MD)¹, Daniel
7 Gonzalez de Requena (BSc, MSc)¹, Mauro Sciandra¹, Jessica Cusato (BSc, MSc)¹, Giulia
8 Troshina (BSc, MSc)², Stefano Bonora (MD)¹, Mario Rizzetto (MD)² and Giovanni Di Perri
9 (MD, PhD)¹.

10 ¹Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy

11 ²Department of Gastroenterology, S.Giovanni Battista (Molinette) Hospital, Turin, Italy

12

13 **Number of Figures and Tables:** 3 and 2, respectively.

14 **SHORT TITLE:** ITPA SNPs and RBV PK predict anemia.

15

16 **Corresponding Author:** Antonio D'Avolio, (BSc, MSc, SM)

17 Tel. +39.011.4393979, Fax: +39.011.4393882; e-mail: antonio.davolio@unito.it;

18 **Keywords:** (Single Nucleotide Polymorphism; Anemia; HCV; Adverse Event; Ribavirin).

19 **List of Abbreviations:** HCV, Hepatitis C virus; SVR, sustained virological response; PEG/IFN,
20 pegylated interferon; RBV, ribavirin; Hb, haemoglobin; Pk, pharmacokinetic; ITPA, inosine
21 triphosphatase; SNPs, single nucleotide polymorphisms; TDM, therapeutic drug monitoring;
22 IQR, inter-quartile range; ROC, receiver operating characteristic.

23 **Conflicts of interest:** The authors disclose no conflicts.

24 **Funding:** This study was not supported.

1 **Abstract.**

2 **Background.** Functional variants of inosine triphosphatase (ITPA) were recently found to
3 protect against ribavirin (RBV)-induced hemolytic anemia. However, no definitive data are yet
4 available on the role of plasma RBV concentrations on Hb decrement. Moreover, no data have
5 been published on the possible interplay between these two factors.

6 **Methods.** A retrospective analysis included 167 patients. The *ITPA* variants rs7270101 and
7 rs1127354 were genotyped and tested using the χ^2 -test for association with hemoglobin (Hb)
8 reduction at week 4. We also investigated, using multivariate logistic regression, the impact of
9 RBV plasma exposure on Hb concentrations.

10 **Results.** Both SNPs were associated with Hb decrease. The carrier of at least one variant allele in
11 the functional *ITPA* SNPs was associated with a lower decrement of Hb (-1.1 g/dL), as
12 compared to patients without a variant allele (-2.75 g/dL; $p=4.09 \times 10^{-8}$). RBV concentrations
13 were not influenced by *ITPA* genotypes. A cut-off of 2.3 $\mu\text{g/mL}$ of RBV was found to be
14 associated with anemia (Area-Under-ROC=0.630, sensitivity=50.0% and specificity=69.5%,
15 $p=0.008$). In multivariate logistic regression analyses the carrier of a variant allele ($p=0.005$) and
16 plasma RBV concentrations below 2.3 $\mu\text{g/mL}$ ($p=0.016$) were independently associated with
17 protection against clinically significant anemia at week 4.

18 **Conclusions.** Although no direct relationship was found between *ITPA* polymorphisms and
19 plasma RBV concentrations, both factors were shown to be significantly associated with anemia.
20 A multivariate regression model based on *ITPA* genetic polymorphisms and RBV trough
21 concentration was developed for predicting the risk of anemia. By relying upon these two
22 variables, an individualized management of anemia seems to be feasible in recipients of
23 PEG/IFN-RBV therapy.

1 **INTRODUCTION.**

2 Hepatitis C virus (HCV) is one of the major causes of liver cirrhosis and hepatocellular
3 carcinoma ¹. Sustained viral response (SVR), defined as undetectable plasma HCV RNA 24
4 weeks after the end of treatment, is achieved in less than 50% of patients with genotype-1
5 infection using the currently recommended regimen consisting of pegylated-interferon
6 (PEG/IFN) and ribavirin ².

7 Anemia is a major untoward effect of anti-HCV chronic therapy. Both PEG/IFN and ribavirin
8 (RBV) play a role in haemoglobin (Hb) decrease, although most of the responsibility is by far
9 attributable to the latter. Moreover, with the forthcoming introduction of the new HCV protease
10 inhibitors, telaprevir and boceprevir, the incidence of anemia is likely to increase, as shown by
11 the results of recent clinical trials ³⁻⁵.

12 Repeatedly, individual RBV dose and pharmacokinetic (Pk) exposure have been found to be
13 consistent determinants of treatment-associated anemia, and recommendations on dose reduction
14 have been released in order to mitigate the impact of RBV on the severity of anemia ⁶⁻¹⁰. Some
15 other studies have not observed an association between hemoglobin decline and plasma RBV
16 concentrations, when multivariate analyses were performed ¹¹⁻¹³.

17
18 Among the non-modifiable individual factors also contributing to anemia development in
19 recipients of anti-HCV therapy, single nucleotide polymorphisms (SNPs) in the human DNA
20 region coding for inosine triphosphatase (ITPA) were identified recently as the most significant
21 variables influencing the risk of anemia. In these studies, by using a genome-wide association
22 approach, two functional variants of ITPA, including one coding and one intronic variant, were
23 found to be associated with treatment-induced anemia in HCV-infected patients ^{5, 14, 15}, as

1 defined by the magnitude of Hb reduction after 4 weeks of treatment. This genetically
2 determined vulnerability was subsequently confirmed in several ethnically heterogeneous
3 clinical cohorts. The association signal was accounted for by 2 functional variants in the *ITPA*
4 gene on chromosome 20: a missense variant in exon 2 (rs1127354, P32T) and a splice-altering
5 single nucleotide polymorphism in intron 2 (rs7270101). Both polymorphisms had previously
6 been well characterized and validated as functional variants in studies of patients with ITPase
7 deficiency, a benign inherited enzymopathy in which inosine triphosphate (the substrate for
8 ITPase) accumulates in red blood cells ^{16, 17}.

9 A recent study established that intraerythrocytic accumulation of ITP, as seen in carriers of such
10 anemia-protecting mutants, provides an alternative source of nucleoside-triphosphates that
11 eventually compensates for RBV-induced ATP reduction ¹⁸.

12 Since it is not known whether any direct relationship exist between *ITPA* polymorphisms and
13 RBV pharmacokinetics, the effects of *ITPA* genetic variants (rs7270101 and rs1127354) and
14 RBV trough concentration on the development of ribavirin-associated anemia at week 4 were
15 retrospectively evaluated in HCV-mono-infected patients who underwent PEG-IFN/RBV
16 therapy, and had complete medical records as well as samples available for genetic and
17 pharmacokinetic analyses. As a simultaneous evaluation of *ITPA* SNPs and plasma RBV
18 concentrations for hemolytic anemia has not yet been published, we aimed to understand the
19 contribution of each factor and any possible interplay between them.

20

1 **PATIENTS AND METHODS.**

2 *Patients*

3 In this retrospective study, 234 patients with chronic HCV infection, treated in two university
4 hospitals (Amedeo di Savoia and S. Giovanni Battista) of the city of Turin, Italy, between March
5 2005 and November 2008 were enrolled.

6 Patients were treated with PEG/IFN- α -2b (1.5 μ g/kg s.c. once a week; sub dermal injection) or
7 PEG/IFN- α -2a (180 μ g once a week; sub dermal injection) plus RBV (600–1400 mg daily
8 depending on bodyweight; orally). Sampling was performed after obtaining written informed
9 consent in accordance with local ethics committee guidelines. Since patients' authorization for
10 routine sampling at the time of treatment did not include genetic analyses for polymorphisms
11 (while therapeutic drug monitoring (TDM) of RBV is performed routinely and authorized on a
12 regular basis since early 2005), patients were asked for an additional authorization for the genetic
13 screening of their stored samples. Main inclusion criteria were: no concomitant interacting drugs,
14 self-reported adherence > 95%, no RBV and/or PEG/IFN dose modification up to week 4 of
15 treatment and no treatment with growth factor before week 4. Patients with other forms of liver
16 disease, active hepatitis A, hepatitis B infection, HIV infection, decompensated liver disease,
17 hepatocellular carcinoma, severe depression or other psychiatric diseases, significant cardiac or
18 renal disease, seizure disorders or pregnancy were excluded from this study. Data collected
19 included: age, gender, weight, previous IFN therapy, concomitant drugs, baseline and week 2
20 and 4 biochemical parameters, such as white blood cells, Hb, alanine transaminase (ALT) level,
21 serum HCV RNA level (logIU/mL).

22

23

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Genotyping

Patients from whom DNA samples were available and who agreed to undergo genetic analyses were genotyped at polymorphic sites rs1127354, rs7270101 and rs6051702 on chromosome 20 using the ABI TaqMan allelic discrimination kit by real time PCR using standard methodology. All primers, probes, and PCR conditions are available on request. The possible genotypes for each biallelic polymorphism are as follows: rs1127354: C/C, A/C, A/A (minor allele = A); rs7270101: A/A, A/C, C/C (minor allele = C); rs6051702: A/A, A/C, C/C (minor allele = C).

Measurement of plasma ribavirin concentration

At week 4, a time associated with the achievement of RBV steady-state¹⁹, plasma samples were collected ~12 h after the dose administration of RBV, just before the following administration (trough value). Samples were centrifuged at 3000 rpm for 10 minutes to separate plasma and then stored at -80°C until analysis. Ribavirin concentrations were measured by a previously validated HPLC method²⁰. Briefly, the extraction of RBV from an aliquot of 250 µL of plasma was performed using 1500 µL of acetonitrile. The mixture was vortexed for 10 seconds and then centrifuged at 12,000×g for 10 minutes at 4°C and the supernatant was dried at 50°C. The dry extract was reconstituted with 125 µL of mobile phase then 30 µL was injected onto the column. Chromatographic separation was performed by an Atlantis 3µm dC18 column (150mm×4.6mm I.D, Waters, Milan, Italy), and RBV peak was detected at a wave length of 235 nm and retention time of 4.3 minutes. The calibration curve ranged from 0.078 to 10 µg/mL. Accuracy and precision standard errors were below 10%.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Definition of Clinical End Points

In common with most therapeutic studies on HCV chronic hepatitis treatment, Hb decline at week 4 was taken as the clinical endpoint and patients were classified according to two clinical cut-off: (a) absolute Hb value lower than 10 g/dL, and (b) Hb reduction >3 g/dL at week 4.

Statistical Analysis

For descriptive statistics, continuous variables were summarized as median (25th to 75th percentiles). Categorical variables were described as frequency and percentage. All data were assessed for normality using a Shapiro-Wilk test and categorical data were compared using a Mann Whitney or Kruskal-Wallis statistical test. To investigate continuous data, a Spearman Rank correlation was utilized. The association between individual ITPA SNP and the incidence of significant Hb decline was tested by a basic allelic test and calculated using the χ^2 -test. Receiver operating characteristic (ROC) curves were used to calculate cut-off values. Multivariate logistic regression analysis with stepwise forward selection was performed with *P*-values of less than 0.05 as the criteria for model inclusion. Statistical analyses were conducted by using SPSS software package ver. 18.0 (Chicago, IL, USA) and using Prism 5.0 (GraphPad Software, San Diego, USA). Linkage disequilibrium analysis was conducted considering r^2 and using Haploview 4.2.

1 **RESULTS.**

2 Sixty-seven out of 234 patients were excluded due to the lack of demographic and clinical
3 information, including RBV plasma evaluation at week 4.

4 Of the 167 patients included in the analysis, 90 patients (53.9%) were male, the median age was
5 46 years (IQR, 38–58 years) and the median body weight was 69 kg (IQR, 62–75 kg). 161
6 patients (96.4%) were Caucasian and 6 (3.6%) were African. 81 patients (48.5%) were treated
7 with PEG/IFN-a-2a (180 µg/ once a week) and 86 (51.5%) were treated with PEG/IFN-a-2b (1.5
8 µg/kg s.c. once a week). The median dose of RBV was 14.01 mg/kg (12.68-15.38). The majority
9 of patients were treated with 800 mg (n=51) or 1000 mg (n=103) of RBV; three patients received
10 600mg, nine 1200 mg and one 1400 mg.

11 The median Hb reduction was -2.4 g/dL (-3.5 to -1.3) at week 4. 59 patients (35.3%) had anemia
12 (Hb reduction>3g/dL or Hb<10g/dL) at week 4. Baseline Hb was correlated with Hb reduction
13 ($\rho=-0.429$ $p=7.15 \times 10^{-9}$).

14 The variant allele frequencies for rs1127354 C/A, rs7270101 A/C and rs6051702 A/C were
15 4.8%, 11.1%, and 13.7%, respectively. All SNPs were in Hardy-Weinburg equilibrium. The
16 three SNPs in analysis did not result in Linkage Disequilibrium ($r^2<0.5$) in our population. No
17 differences concerning demographic, racial, physical characteristics and biochemical parameters,
18 (Hb, platelet count, alanine transaminase -ALT- level, serum HCV RNA level) were observed
19 among genetically defined groups.

20 The two functional ITPA SNPs, responsible for inosine triphosphatase deficiency, (rs1127354
21 and rs7270101) and the co-segregate SNP (rs6051702) were associated with the magnitude of
22 hemoglobin decrease. Patients with rs1127354CC (n=151) had a larger hemoglobin decrement (-
23 2.5 g/dL, IQR -3.6 to -1.4), as compared to patients with CA/AA genotypes (-0.8 g/dL, IQR -1.1

1 to -0.4, $p=3.06 \times 10^{-6}$). Similarly patients with genotype rs7270101AA (n=133) had a larger
2 hemoglobin decrement (-2.5 g/dL, IQR -3.6 to -1.4), as compared to patients with AC/CC (-1.7
3 g/dL, IQR -2.5 to -0.7, $p = 0.002$) and patients with rs6051702AA (n=129) had a larger
4 hemoglobin decrement (-2.7 g/dL, IQR -3.7 to -1.7) as compared to patients with AC/CC (-1.1
5 g/dL, IQR -1.9 to -0.7, $p=3.4 \times 10^{-9}$).

6 Despite the strong association between the hemoglobin decrement and the polymorphism
7 rs6051702, in the following statistical analysis we have considered only the two functional
8 polymorphisms of the gene ITPA, as described by other authors^{5, 21, 22}.

9 As showed in Figure 1, the carrier of at least one variant allele in the functional ITPA SNPs was
10 associated with a smaller decrement of Hb ($p=4.09 \times 10^{-8}$). In particular, patients with at least a
11 variant allele in the functional ITPA SNPs (n=49) had a lower hemoglobin decrement (-1.1 g/dL,
12 IQR -2.3 to -0.6), as compared to patients (n=118) without a variant allele (-2.75 g/dL, IQR -3.7
13 to -1.7). No differences in Hb baseline between the wild type genotype patients and the carriers
14 of a least one mutation for ITPA gene were observed ($p=0.843$).

15 Median trough plasma RBV concentrations at week 4 were 2.1 $\mu\text{g/mL}$ (1.63 to 2.68). Weight at
16 baseline ($\rho=-0.286$ $p=4.0 \times 10^{-4}$) and dose/kg of RBV ($\rho=0.265$ $p=0.001$) were correlated with
17 plasma RBV concentrations.

18 RBV concentrations were not influenced by ITPA genotypes. Patients with rs1127354CC had a
19 median RBV concentration of 2.1 $\mu\text{g/mL}$ (1.63 to 2.68) compared with 1.76 $\mu\text{g/mL}$ (1.50 to 2.6,
20 $p=0.269$) in patients with the CA/AA genotype. Similarly patients with rs7270101AA had a
21 median RBV concentration of 2.09 $\mu\text{g/mL}$ (1.63 to 2.68) compared with 2.1 $\mu\text{g/mL}$ (1.63 to 2.90,
22 $p=0.795$) in patients with the rs7270101 AC/CC genotype. A trend towards higher RBV
23 concentrations could be observed in patients with rs6051702AA with a median of 2.14 $\mu\text{g/mL}$

1 (1.68 to 2.82), while patients characterized by rs6051702 AC/CC genotypes had median of 1.83
2 $\mu\text{g/mL}$ (1.47 to 2.20, $p=0.067$). Plasma RBV concentrations at week 4 were correlated with Hb
3 reduction at week 4 ($\rho=-0.183$ $p=0.025$).

4 To define the clinical relevance of genetic variants, trough concentration of RBV and other
5 variables, we analyzed the proportion of patients with clinically significant anemia, which was
6 defined as a decline of Hb more than 3 g/dL or an absolute Hb value lower than 10 g/dL. As
7 summarized in Table 1, differences could be detected for baseline Hb, RBV trough
8 concentrations and possession of variant alleles in the two SNPs.

9 By using ROC curve analysis, a cut-off of plasma RBV concentration of 2.3 $\mu\text{g/mL}$ was found to
10 be associated with anemia (Area-Under-ROC=0.630, sensitivity=50.0% and specificity=69.5%,
11 $p=0.008$). Using this cut-off, 30 out of 59 (50.8%) patients with a RBV concentration above 2.3
12 $\mu\text{g/mL}$ developed anemia, while this occurred in only 27/108 (25.0%) patients with RBV
13 concentrations below 2.3 $\mu\text{g/mL}$ ($\chi^2=8.08$, $p=0.003$).

14 Many factors previously linked to anemia were also included in multivariate logistic regression
15 analysis. As summarized in Table 2, carrier of variant allele (OR=0.29, $p=0.005$) and RBV
16 plasma concentrations below 2.3 $\mu\text{g/mL}$ (OR=0.42, $p=0.016$) were independently associated with
17 protection against clinically significant anemia. The probability of developing anemia based on
18 these two predictive factors is shown in Figure 2. Considering patients with RBV concentrations
19 below 2.3 $\mu\text{g/mL}$, the predicted probability of developing anemia was 35.5% for patients with
20 wild type genotype for all SNPs ($n=72$) and 13.8% for patients with at least one SNP with a
21 variant allele ($n=31$). Considering patients with RBV concentrations above 2.3 $\mu\text{g/mL}$, the
22 predicted probability for patients with wild type genotype for all SNPs ($n=47$) was 56.8%,
23 compared with 27.5% for patients with at least one SNP with variant allele ($n=17$).

1 As shown in Figure 3 carriers of ITPA variants had a smaller decrease of Hb as compared to
2 patients with wild type ITPA genotype. In the same figure and analysis it is also apparent that,
3 regardless of the RBV concentration, in carriers of ITPA variants the magnitude of Hb
4 decrement was found to have no significant association with plasma RBV concentration ($\rho=-$
5 0.17 , $p=0.28$), while the magnitude of Hb decrease among patients with the WT ITPA genotype
6 had a strong and significant association with RBV concentrations ($\rho=-0.20$, $p=0.035$).

1 **DISCUSSION.**

2 Recently several genetic variants associated with substantial effects on both efficacy and toxicity
3 of PEG/IFN and ribavirin have been identified. SNPs in the *IL28B* gene were found to be
4 strongly associated with response to therapy of chronic genotype 1 HCV infection ²³⁻²⁷, and
5 SNPs in the *ITPA* gene were identified as predictors of RBV treatment-associated anemia in the
6 European-American and Japanese populations ^{5, 14, 15, 28}. The anemia experienced as a
7 consequence of PEG/IFN and RBV combination therapy is primarily caused by a RBV-induced
8 haemolysis and secondarily by interferon-induced bone marrow toxicity. Ribavirin toxicity can
9 be explained by the accumulation of RBV phosphate metabolites in erythrocytes, oxidative
10 damage and consequent cell lysis ²⁹. The impact of anemia on the outcome of anti-HCV infection
11 therapy is substantial, since RBV dose-reduction or early treatment interruption due to anemia
12 often leads to suboptimal drug intake and a higher chance of treatment failure ³⁰. The possibility
13 of identifying those patients who are more likely to undergo significant Hb loss while on
14 treatment might be helpful in order to implement those measures which might limit the impact
15 of anemia on treatment outcome.

16 In this study the newly identified genetic polymorphisms of *ITPA* as well as RBV
17 pharmacokinetic exposure, using RBV trough plasma concentration, confirmed their value as
18 predictors of treatment-induced anemia, as established by HB reduction after 4 weeks of
19 PEG/IFN-RBV treatment. Furthermore, we observed that baseline Hb was correlated with Hb
20 reduction. However having a higher baseline HB concentration is a biologically benign
21 condition, which testifies to a higher functional reserve as compared to the other patients. For
22 pure numerical reasons such condition is more vulnerable to a HB loss, since HB loss is here
23 measured in terms of absolute values rather than percentage HB loss from baseline.

1 Although, in addition to ITPA polymorphisms and RBV concentration, a series of individual
2 features such as age, platelet count, haemoglobin concentration and haptoglobin phenotype were
3 found to have some degree of association with the risk of anemia ^{8, 31, 32}, the only modifiable
4 factor of these variables is RBV pharmacokinetic exposure, which shows remarkable variability
5 among HCV-infected patients ³³. Thus, the early assessment of RBV concentration is suggested
6 by some studies ^{34, 35} in order to adjust individual RBV dose.

7 Following the identification of ITPA polymorphism as the strongest predictor of anemia in
8 PEG/IFN-RBV recipients, the question arises as to how to integrate this newly identified genetic
9 marker with RBV trough concentration in order to predict and manage the individual risk of
10 anemia. According to our results, there is no apparent correlation between ITPA polymorphisms
11 and RBV pharmacokinetic exposure, as also expected by the reported lack of association
12 between ITPA polymorphism and treatment outcome.

13 Thus, the two variables analyzed here, ITPA functional polymorphism and RBV concentration,
14 retain their independent predictive values and display limited overlap in terms of predictive
15 value. As shown in figure 2, the reciprocal increase in predictive value provided by either
16 variable is significant. When relying upon RBV exposure, it is apparent that with high RBV
17 concentration the possession of ITPA variants is associated with a lower risk of anemia as
18 compared to patients with WT genotype and, changing the point of view, patients with the same
19 ITPA genetic profile have a higher risk of anemia in case of higher RBV concentration.

20 Thus, the introduction of the described ITPA genetic polymorphism substantially improves our
21 ability to predict the individual risk of treatment-induced anemia (perhaps also considering the
22 non-functional polymorphism rs6051702?). The main implication of our results is that the
23 possession of ITPA variants is associated with a rather limited median Hb loss, independent of

1 RBV concentration, even when RBV concentration is above the threshold of 2.3 $\mu\text{g/mL}$. In our
2 patients anemia occurred in 8 of 49 ITPA variant carriers (16.3%) and in 51 of 118 of ITPA WT
3 patients (43.2%). It is worth noting that the only 6 patients who had Hb value less than 10 g/dL
4 at week 4 were all ITPA WT carriers.

5 In practical terms, given that human genetic analysis is easier and quicker to perform, with
6 turnaround time shorter than TDM of RBV, and that the technique is far more widespread than
7 TDM, the baseline estimation of the individual risk of treatment-induced anemia seems now a
8 step closer to becoming common practice. In this perspective, RBV TDM might maintain a role
9 in the management of the prevailing proportion of patients with WT ITPA genotype, in whom
10 RBV concentration may be fruitfully modified by RBV dose adjustment. Since RBV
11 pharmacokinetic exposure is also associated with the rate of SVR^{6, 11, 13, 27, 36, 37}, the same might
12 also apply to carriers of ITPA variants with suboptimal RBV concentration, in whom RBV dose
13 may be increased with a smaller risk of anemia.

14 In conclusion, this retrospective study confirms the high impact of ITPA SNPs on hemolytic
15 anemia and seems to suggest a cut-off value for trough plasma RBV concentration. Although
16 more studies are needed to clarify and confirm the relationship between anemia, ITPA
17 polymorphism and RBV pharmacokinetics, these results show that estimating the risk of anemia
18 by relying upon both these two determinants was more accurate than the use of a single
19 assessment of either variable, assuming plasma RBV concentrations are a key factor to predict
20 anemia. Moreover, these data might form the basis for the development of an individual
21 screening algorithm able to reduce the impact of anemia on the rate of response to anti-HCV
22 treatment.

1 **REFERENCES**

2

3 1 Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-
4 limiting posttransfusion hepatitis C. *Hepatology*. 1995 Mar;21: 639-44.

5 2 Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin
6 combination therapy in chronic hepatitis C: a randomized study of treatment duration and
7 ribavirin dose. *Ann Intern Med*. 2004 Mar 2;140: 346-55.

8 3 Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without
9 ribavirin for chronic HCV infection. *N Engl J Med*. 2009 Apr 30;360: 1839-50.

10 4 Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor,
11 in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with
12 genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2
13 trial. *Lancet*. 2010 Aug 28;376: 705-16.

14 5 Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphisms on decreases of
15 hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. *Hepatology*.
16 2011 Feb;53: 415-21.

17 6 Aguilar Marucco D, Gonzalez de Requena D, Bonora S, et al. The use of trough ribavirin
18 concentration to predict sustained virological response and haematological toxicity in HIV/HCV-
19 co-infected patients treated with ribavirin and pegylated interferon. *J Antimicrob Chemother*.
20 2008 Apr;61: 919-24.

21 7 Kubota R, Komiyama T, Kumagai N, et al. Optimal erythrocyte ribavirin level to reduce
22 the risk of anemia and obtain an early virological response in patients with chronic hepatitis C
23 caused by genotype 1b infection. *Hepat Res Treat*.2010: 495928.

1 8 Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather
2 than dose per kilogram body weight predicts ribavirin-induced anaemia. *J Viral Hepat.* 2004
3 Jan;11: 84-7.

4 9 Mac Nicholas R, Norris S. Review article: optimizing SVR and management of the
5 haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of
6 epoetin, G-CSF and novel agents. *Aliment Pharmacol Ther.* 2010 May;31: 929-37.

7 10 McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in
8 patients infected with hepatitis C virus. *Liver Int.* 2006 May;26: 389-98.

9 11 Breilh D, Foucher J, Castera L, et al. Impact of ribavirin plasma level on sustained
10 virological response in patients treated with pegylated interferon and ribavirin for chronic
11 hepatitis C. *Aliment Pharmacol Ther.* 2009 Sep 1;30: 487-94.

12 12 Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and
13 pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. *Ther Drug Monit.*
14 2000 Oct;22: 555-65.

15 13 Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. Prediction of sustained
16 virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus
17 genotype 1 patients. *Antivir Ther.* 2008;13: 607-11.

18 14 Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in
19 patients treated for chronic hepatitis C. *Nature.* 2010 Mar 18;464: 405-8.

20 15 Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirin-induced anemia
21 and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.
22 *Gastroenterology.* 2010 Oct;139: 1190-7.

1 16 Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N. Measurement of
2 erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation
3 of ITPA genotype-phenotype in a Caucasian population. *Clin Chem.* 2006 Feb;52: 240-7.

4 17 Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate
5 pyrophosphohydrolase deficiency. *Hum Genet.* 2002 Oct;111: 360-7.

6 18 Hitomi Y, Cirulli ET, Fellay J, et al. Inosine Triphosphate Protects Against Ribavirin-
7 Induced Adenosine Triphosphate Loss by Restoring Adenylosuccinate Synthase Function.
8 *Gastroenterology.* 2011 Jan 1.

9 19 Slavenburg S, Huntjens-Fleuren HW, Dofferhoff TS, et al. Ribavirin plasma
10 concentration measurements in patients with hepatitis C: early ribavirin concentrations predict
11 steady-state concentrations. *Ther Drug Monit.* 2011 Feb;33: 40-4.

12 20 D'Avolio A, Ibanez A, Sciandra M, et al. Validation of liquid/liquid extraction method
13 coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. *J*
14 *Chromatogr B Analyt Technol Biomed Life Sci.* 2006 May 1;835: 127-30.

15 21 Kurosaki M, Tanaka Y, Tanaka K, et al. Relationship between polymorphisms of the
16 inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon
17 and ribavirin. *Antivir Ther.* 2011;16: 685-94.

18 22 Thompson AJ, Santoro R, Piazzolla V, et al. Inosine triphosphatase genetic variants are
19 protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose
20 reductions of RBV or increase SVR. *Hepatology.* 2010 Feb;53: 389-95.

21 23 Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C
22 treatment-induced viral clearance. *Nature.* 2009 Sep 17;461: 399-401.

1 24 Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to
2 chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet.* 2009 Oct;41: 1100-4.

3 25 Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with
4 response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet.*
5 2009 Oct;41: 1105-9.

6 26 Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves
7 viral kinetics and is the strongest pretreatment predictor of sustained virologic response in
8 genotype 1 hepatitis C virus. *Gastroenterology.* 2010 Jul;139: 120-9.

9 27 D'Avolio A, Ciancio A, Siccardi M, et al. Ribavirin pharmacokinetics and interleukin
10 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to
11 pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4.
12 *Hepatology.* 2011 Dec;54: 2279.

13 28 Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects against anemia
14 induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic
15 hepatitis C. *Hepatol Res.* 2010 Nov;40: 1063-71.

16 29 De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin
17 therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.
18 *Hepatology.* 2000 Apr;31: 997-1004.

19 30 Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for
20 chronic hepatitis C virus infection. *N Engl J Med.* 2002 Sep 26;347: 975-82.

21 31 Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced
22 anemia. *J Gastroenterol Hepatol.* 2004 Nov;19: 1312-7.

1 32 Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G. Factors influencing
2 ribavirin-induced hemolysis. *J Hepatol.* 2001 Jun;34: 911-6.

3 33 Tsubota A, Hirose Y, Izumi N, Kumada H. Pharmacokinetics of ribavirin in combined
4 interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. *Br J Clin*
5 *Pharmacol.* 2003 Apr;55: 360-7.

6 34 Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is
7 predictive of sustained virological response in chronic hepatitis C. *Hepatology.* 2008 May;47:
8 1453-61.


9 35 Morello J, Rodriguez-Novoa S, Jimenez-Nacher I, Soriano V. Usefulness of monitoring
10 ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis
11 C. *J Antimicrob Chemother.* 2008 Dec;62: 1174-80.

12 36 Pedersen C, Alsio A, Lagging M, et al. Ribavirin plasma concentration is a predictor of
13 sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3
14 infection. *J Viral Hepat.* 2011 Apr;18: 245-51.

15 37 van Vlerken LG, van Oijen MG, van Erpecum KJ. Ribavirin concentration is a more
16 important predictor of sustained viral response than anemia in hepatitis C patients.
17 *Gastroenterology.* 2011 May;140: 1693-4.
18
19

1 **Figure Legends.**


2 **Figure 1.** The possession of at least one variant allele in the functional ITPA SNPs (n=49) was
3 associated with a smaller decrement of Hb (g/dL) at week 4 ($p=4.09 \times 10^{-8}$). Median values
4 (horizontal line), IQR (bars), patient values (black square), highest and lowest value (whiskers)
5 are shown.



6

7

1
2 **Figure 2.** The predicted probability of developing anemia considering the possession of variant
3 alleles and RBV concentrations (cut-off of 2.3 $\mu\text{g/mL}$) in multivariate logistic regression. The
4 predicted probability of anemia is 13.8% for Yes-Carrier and Yes-RBV<2.3, 27.5% for Yes-
5 Carrier and No-RBV<2.3, 35.5% for No-Carrier and Yes-RBV<2.3 and 56.8% for No-Carrier
6 and No-RBV<2.3.



7
8

1
2 **Figure 3.** Scatter plot representing the correlation between RBV concentrations at week 4
3 ($\mu\text{g/mL}$) and Hb reduction at week 4 (g/dL). Patient values (black dots for ITPA wild type and
4 white square for ITPA variant carrier), linear regression (filled line for ITPA wild type and
5 dotted line for ITPA variant carrier) are shown. Patients with the wild type ITPA genotype had a
6 strong and significant association with RBV concentrations ($\rho=-0.20$, $p=0.035$).

